{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:56:17Z","timestamp":1792616177005,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2021PY065"],"award-info":[{"award-number":["2021PY065"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2020PY064"],"award-info":[{"award-number":["2020PY064"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2020KY238"],"award-info":[{"award-number":["2020KY238"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY951"],"award-info":[{"award-number":["2021KY951"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LGF21H190002"],"award-info":[{"award-number":["LGF21H190002"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LGF21H260007"],"award-info":[{"award-number":["LGF21H260007"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jinf.2026.106871","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:40:48Z","timestamp":1791092448000},"page":"106871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of pharmacological regimens for Mycobacterium avium complex pulmonary disease and bacteremia: A systematic review with separate network meta-analyses"],"prefix":"10.1016","volume":"93","author":[{"given":"Qinglin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoqi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiancheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jinf.2026.106871_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.jinf.2026.106871_bib2","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/ciae421","article-title":"Nontuberculous mycobacterial pulmonary disease: patients, principles, and prospects","volume":"79","author":"Nguyen","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2026.106871_bib3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/17476348.2023.2283135","article-title":"A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges","volume":"17","author":"Hamed","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jinf.2026.106871_bib4","series-title":"Disseminated Mycobacterium avium complex: Adult and adolescent opportunistic infections guidelines","author":"National Institutes of Health","year":"2025"},{"issue":"4","key":"10.1016\/j.jinf.2026.106871_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib6","series-title":"Disseminated Mycobacterium avium complex disease. In: Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV","author":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV","year":"2024"},{"issue":"7","key":"10.1016\/j.jinf.2026.106871_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2026.106871_bib8","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jinf.2026.106871_bib9","article-title":"Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics","volume":"28","author":"Schildkraut","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.jinf.2026.106871_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2023","article-title":"Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint","volume":"63","author":"van Ingen","year":"2024","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jinf.2026.106871_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1513\/AnnalsATS.202408-904FR","article-title":"Comprehensive management algorithm for Mycobacterium avium complex pulmonary disease in the real-world setting","volume":"22","author":"Morimoto","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jinf.2026.106871_bib12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"7521","key":"10.1016\/j.jinf.2026.106871_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2026.106871_bib14","unstructured":"Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al., editors. Cochrane handbook for systematic reviews of interventions. Version 6.5. Cochrane; 2024."},{"issue":"1","key":"10.1016\/j.jinf.2026.106871_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s44350-026-00012-1","article-title":"Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"2","author":"Kang","year":"2026","journal-title":"Mycobacteria"},{"issue":"6","key":"10.1016\/j.jinf.2026.106871_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf292","article-title":"Treatment outcomes of Mycobacterium avium complex pulmonary disease with a 2-drug daily regimen using macrolide and ethambutol","volume":"12","author":"Im","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2026.106871_bib17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jmii.2025.03.018","article-title":"Aminoglycoside susceptibility and treatment outcomes in Mycobacterium avium complex pulmonary disease","volume":"58","author":"Chang","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.jinf.2026.106871_bib18","first-page":"545","article-title":"Mycobacterium avium complex disease: current treatment challenges and future directions","volume":"43","author":"Daley","year":"2022","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jinf.2026.106871_bib19","series-title":"WHO guidelines on the management of advanced HIV disease","author":"World Health Organization","year":"2025"},{"issue":"2","key":"10.1016\/j.jinf.2026.106871_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/09564624241297835","article-title":"Mycobacterium avium complex (MAC) infection in severely immunocompromised people living with HIV: findings from a five-year cohort","volume":"36","author":"Fern\u00e1ndez-D\u00edaz","year":"2025","journal-title":"Int J STD AIDS"},{"issue":"12","key":"10.1016\/j.jinf.2026.106871_bib21","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/infdis\/jiaa669","article-title":"Clinical and immunologic predictors of Mycobacterium avium complex immune reconstitution inflammatory syndrome in a contemporary cohort of patients with human immunodeficiency virus","volume":"223","author":"Breglio","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111985","article-title":"Updating the PRISMA reporting guideline for network meta-analysis: a scoping review","volume":"188","author":"Veroniki","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jinf.2026.106871_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid Synth"},{"issue":"1","key":"10.1016\/j.jinf.2026.106871_bib24","first-page":"4","article-title":"The Newcastle\u2013Ottawa Scale for assessing the quality of studies in systematic reviews","volume":"14","author":"Gualdi-Russo","year":"2026","journal-title":"Publ (Basel)"},{"key":"10.1016\/j.jinf.2026.106871_bib25","article-title":"Comparative efficacy and acceptability of psychosocial interventions for PTSD, depression, and anxiety in asylum seekers, refugees, and other migrant populations: a systematic review and network meta-analysis of randomised controlled studies","volume":"48","author":"Turrini","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.jinf.2026.106871_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2026.106871_bib27","article-title":"Changes in sputum microbiota during treatment for nontuberculous mycobacterial pulmonary disease","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jinf.2026.106871_bib28","first-page":"517","article-title":"Safety and efficacy of nontuberculous mycobacteria treatment among elderly patients","volume":"56","author":"Uchida","year":"2020","journal-title":"Med (Kaunas)"},{"key":"10.1016\/j.jinf.2026.106871_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cpp.3042","article-title":"Psychological interventions for PTSD, depression, and anxiety in child, adolescent and adult forced migrants: a systematic review and frequentist and Bayesian meta-analyses","volume":"31","author":"Molendijk","year":"2024","journal-title":"Clin Psychol Psychother"},{"key":"10.1016\/j.jinf.2026.106871_bib30","article-title":"Using selection models to assess sensitivity to publication bias: a tutorial and call for more routine use","volume":"18","author":"Maier","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.jinf.2026.106871_bib31","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1378\/chest.107.4.1035","article-title":"Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS","volume":"107","author":"Dautzenberg","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2026.106871_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199608083350602","article-title":"Canadian HIV Trials Network Protocol 010 Study Group. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin","volume":"335","author":"Shafran","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2026.106871_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00002030-199703110-00008","article-title":"Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection","volume":"11","author":"Chaisson","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2026.106871_bib34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/514116","article-title":"California Collaborative Treatment Group. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy","volume":"176","author":"Dub\u00e9","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1086\/513753","article-title":"ANRS Trial 033 Curavium Group. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium","volume":"25","author":"May","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib36","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1086\/514999","article-title":"Veterans Affairs HIV Research Consortium. Randomized, open-label trial of azithromycin plus ethambutol vs clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection","volume":"27","author":"Ward","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1086\/520141","volume":"29","author":"Cohn","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s100960050220","article-title":"Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients","volume":"18","author":"Fournier","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib39","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/514748","article-title":"A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib40","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1086\/317468","article-title":"A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus","volume":"31","author":"Dunne","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib41","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/378807","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jinf.2026.106871_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease: a preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jinf.2026.106871_bib44","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2026.106871_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jiac.2017.01.007","article-title":"The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: a nationwide post-marketing study","volume":"23","author":"Kadota","year":"2017","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jinf.2026.106871_bib46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2026.106871_bib47","doi-asserted-by":"crossref","first-page":"00466-2021","DOI":"10.1183\/23120541.00466-2021","article-title":"Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study","volume":"7","author":"Zweijpfenning","year":"2021","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.jinf.2026.106871_bib48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jinf.2026.106871_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/tropicalmed7020027","article-title":"Factors associated with treatment outcome in patients with nontuberculous mycobacterial pulmonary disease: a large population-based retrospective cohort study in Shanghai","volume":"7","author":"Cheng","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib50","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jinf.2026.106871_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad682","article-title":"Treatment outcomes of clofazimine-containing regimens in severe Mycobacterium avium complex pulmonary disease","volume":"11","author":"Lee","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2026.106871_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107718","article-title":"Clofazimine serum concentration and safety\/efficacy in nontuberculous mycobacterial pulmonary disease treatment","volume":"231","author":"Watanabe","year":"2024","journal-title":"Respir Med"},{"issue":"21","key":"10.1016\/j.jinf.2026.106871_bib53","first-page":"16","article-title":"Analyses on clinical characteristics and related factors of treatment outcomes in patients with nontuberculous mycobacterial pulmonary disease","volume":"62","author":"Zhou","year":"2024","journal-title":"China Mod Dr"},{"issue":"6","key":"10.1016\/j.jinf.2026.106871_bib54","first-page":"720","article-title":"Characteristics of patients with non-tuberculous mycobacterium pulmonary disease and influencing factors of treatment outcomes in Wuxi, Jiangsu","volume":"25","author":"Mao","year":"2025","journal-title":"China Trop Med"},{"issue":"4","key":"10.1016\/j.jinf.2026.106871_bib55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/annalsats\/aaoaf064","article-title":"Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial","volume":"23","author":"Daley","year":"2026","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jinf.2026.106871_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-026-02787-x","article-title":"Treatment outcomes of clofazimine-containing regimens in Mycobacterium avium complex pulmonary disease: a retrospective study from two European reference centers","author":"Piccirillo","year":"2026","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2026.106871_bib57","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jinf.2026.106871_bib58","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12890-024-03261-w","article-title":"Effectiveness of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease in Japanese clinical practice","volume":"24","author":"Urabe","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.jinf.2026.106871_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01157-23","article-title":"Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model","volume":"68","author":"Salillas","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jinf.2026.106871_bib60","first-page":"1620","article-title":"Amikacin liposomal inhalation suspension for non-tuberculous Mycobacteria lung infection: a greek observational study","volume":"60","author":"Loukeri","year":"2024","journal-title":"Med (Kaunas)"},{"key":"10.1016\/j.jinf.2026.106871_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jinf.2026.106871_bib62","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-026-04413-w","article-title":"Clinical factors and practical strategies to optimize amikacin liposome inhalation suspension therapy in refractory Mycobacterium avium complex pulmonary disease","author":"Kurosaki","year":"2026","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.jinf.2026.106871_bib63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4046\/trd.2023.0120","article-title":"Real-world outcomes of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease","volume":"87","author":"Kim","year":"2024","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":". 4","key":"10.1016\/j.jinf.2026.106871_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.13727","article-title":"British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of non-tuberculous mycobacteria 2024","volume":"25","author":"Nelson","year":"2024","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2026.106871_bib65","unstructured":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Disseminated Mycobacterium avium complex disease. ClinicalInfo.HIV.gov; updated 27 May 2026."},{"issue":"1","key":"10.1016\/j.jinf.2026.106871_bib66","first-page":"91","article-title":"Expert consensus on diagnosis and treatment of non-tuberculous mycobacteria co-infection in patients with HIV\/AIDS","volume":"32","author":"Professional Committee on HIV Co-infection with Tuberculosis of the Chinese Association of STD\/AIDS Prevention and Control","year":"2026","journal-title":"Chin J AIDS STD"},{"issue":"161","key":"10.1016\/j.jinf.2026.106871_bib67","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0010-2021","article-title":"Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections","volume":"30","author":"Chalmers","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.jinf.2026.106871_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12890-019-0982-8","article-title":"Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"5","key":"10.1016\/j.jinf.2026.106871_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.102711","article-title":"Two-drug versus three-drug regimens for treating Mycobacterium avium complex infection: a systematic review and meta-analysis","volume":"18","author":"Nguyen","year":"2025","journal-title":"J Infect Public Health"},{"issue":"2","key":"10.1016\/j.jinf.2026.106871_bib70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"10.1016\/j.jinf.2026.106871_bib71","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/pathogens12111331","article-title":"A systematic review of factors associated with mortality among patients with Mycobacterium avium complex lung disease","volume":"12","author":"Fujishima","year":"2023","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.jinf.2026.106871_bib72","doi-asserted-by":"crossref","first-page":"00610-2023","DOI":"10.1183\/23120541.00610-2023","article-title":"Mycobacterium avium complex pulmonary disease patients with limited treatment options","volume":"10","author":"Aliberti","year":"2024","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.jinf.2026.106871_bib73","doi-asserted-by":"crossref","DOI":"10.12771\/emj.2025.00080","article-title":"Current and emerging treatment strategies for Mycobacterium avium complex pulmonary disease: a narrative review","volume":"48","author":"Chung","year":"2025","journal-title":"Ewha Med J"},{"issue":"1","key":"10.1016\/j.jinf.2026.106871_bib74","article-title":"Treatment strategies for Mycobacterium avium pulmonary disease","volume":"22","author":"Winther","year":"2026","journal-title":"Breathe (Sheff)"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:27:29Z","timestamp":1792614449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0163445326001970"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106871","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of pharmacological regimens for Mycobacterium avium complex pulmonary disease and bacteremia: A systematic review with separate network meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106871"}}